CANCER TREATMENT REGIMENS
Cancer therapy selection, dosing, administration, and the management of related adverse events can be a complex process that should be handled by an experienced healthcare team. Clinicians must choose and verify treatment options based on the individual patient; drug dose modifications and supportive care interventions should be administered accordingly. The cancer treatment regimens below may include both U.S. Food and Drug Administration-approved and unapproved indications/regimens. These regimens are only provided to supplement the latest treatment strategies.
These Guidelines are a work in progress that may be refined as often as new significant data becomes available. The NCCN Guidelines® are a consensus statement of its authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
Cancer Therapy Advisor Articles
- MM-398: A Potential New Option for Metastatic Pancreatic Cancer?
- Disappointing Results for Dual Anti-HER2 Therapy Without Chemotherapy
- Ovarian Suppression Improves Prevention of HR-Positive Breast Cancer Recurrence
- Incidence and prognostic impact of high-risk HPV tumor infection in cervical esophageal carcinoma
- Adding Bortezomib to Fulvestrant Might Improve Outcomes for ER+ Metastatic Breast Cancer
- Researchers Identify Mechanism by Which NSAIDs Prevent Colon Cancer
- Non-Hodgkin Lymphoma (NHL) Treatment Regimens: Burkitt Lymphoma
- Chemoradiation Therapy May Benefit Some Patients with Resectable Gastric Cancer
- Linifanib Fails to Meet Overall Survival Endpoint for Advanced Hepatocellular Carcinoma
- Adding Carfilzomib to Lenalidomide Improves Survival in Relapsed Multiple Myeloma
- For Advanced Non-Small Cell Lung Cancer (NSCLC), Nintedanib Improves Overall Survival Without Reducing Quality of Life
- Dose-Adjusted R-EPOCH Provides Long-Term Benefit for High-Risk Large B-Cell Lymphoma
- miniDOX Chemotherapy for Patients with Advanced Gastric Cancer
- Selenium, Aspirin May Have Benefit in Prostate Cancer
- More Activity, Less Television Reduces Mortality in Colorectal Cancer Survivors